">

Theravance Biopharma?s (TBPH) ?Strong-Buy? Rating Reaffirmed at Zacks Investment Research

Zacks Investment Research?reaffirmed their strong-buy rating on shares of?Theravance Biopharma (NASDAQ:TBPH)?in a research note issued to investors on Friday morning. They currently have a $29.00 target price on the biopharmaceutical company?s stock.

According to Zacks, ?Theravance Biopharma has a single marketed product in its portfolio called Vibativ. We are upbeat about Theravance?s efforts to expand Vibativ?s label, which if approved for additional indications, would be commercially significant. Moreover, its pipeline programs target highly competitive therapeutic areas. The company’s collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as in the past. Shares of the company have outperformed the industry in the past six months. Meanwhile, the company?s regulatory filing for Yupelri (revefenacin) for COPD was accepted by the FDA in January 2018 with a response expected by the year end.?

TBPH has been the topic of several other reports.?ValuEngine?downgraded Theravance Biopharma from a buy rating to a hold rating in a report on Thursday, November 1st. Needham & Company LLC reaffirmed a buy rating and set a $40.00 target price on shares of Theravance Biopharma in a report on Wednesday, August 1st. Leerink Swann set a $38.00 price objective on Theravance Biopharma and gave the company a buy rating in a research note on Wednesday, November 7th. BidaskClub downgraded Theravance Biopharma from a buy rating to a hold rating in a research note on Wednesday, October 24th. Finally, Cantor Fitzgerald reissued a buy rating and issued a $55.00 price objective on shares of Theravance Biopharma in a research note on Monday, October 22nd. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company?s stock. The stock presently has a consensus rating of Buy and an average target price of $43.40.

Shares of?TBPH?opened at $26.24 on Friday. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -4.81 and a beta of 2.09. Theravance Biopharma has a 12 month low of $21.27 and a 12 month high of $35.48. The company has a debt-to-equity ratio of 6.52, a quick ratio of 3.08 and a current ratio of 3.26.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the Thomson Reuters? consensus estimate of ($1.18) by $0.08. The firm had revenue of $12.84 million for the quarter, compared to the consensus estimate of $10.55 million. Theravance Biopharma had a negative return on equity of 505.90% and a negative net margin of 513.41%. On average, equities research analysts forecast that Theravance Biopharma will post -4.19 EPS for the current year.

In related news, EVP Bradford J. Shafer sold 7,119 shares of the company?s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $27.71, for a total transaction of $197,267.49. Following the transaction, the executive vice president now directly owns 84,000 shares of the company?s stock, valued at approximately $2,327,640. The transaction was disclosed in a document filed with the SEC, which can be accessed through?this link. Also, SVP Philip D. Worboys sold 6,393 shares of the company?s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $28.50, for a total value of $182,200.50. Following the transaction, the senior vice president now directly owns 166,753 shares in the company, valued at $4,752,460.50. The disclosure for this sale can be found?here. 6.90% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the stock. Woodford Investment Management Ltd raised its stake in Theravance Biopharma by 2.9% during the 2nd quarter. Woodford Investment Management Ltd now owns 11,213,879 shares of the biopharmaceutical company?s stock worth $254,331,000 after buying an additional 315,000 shares during the period. BlackRock Inc. raised its stake in Theravance Biopharma by 2.2% during the 3rd quarter. BlackRock Inc. now owns 3,833,409 shares of the biopharmaceutical company?s stock worth $125,239,000 after buying an additional 82,620 shares during the period. Northern Trust Corp raised its stake in Theravance Biopharma by 3.6% during the 2nd quarter. Northern Trust Corp now owns 535,284 shares of the biopharmaceutical company?s stock worth $12,140,000 after buying an additional 18,733 shares during the period. Chescapmanager LLC raised its stake in Theravance Biopharma by 15.0% during the 2nd quarter. Chescapmanager LLC now owns 403,321 shares of the biopharmaceutical company?s stock worth $9,147,000 after buying an additional 52,690 shares during the period. Finally, State of New Jersey Common Pension Fund D raised its stake in Theravance Biopharma by 17.7% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 265,459 shares of the biopharmaceutical company?s stock worth $6,021,000 after buying an additional 40,000 shares during the period. 84.31% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.